论文部分内容阅读
目的评估甲羟孕酮在晚期子宫内膜癌维持治疗中的疗效。方法 40例一线化疗后的晚期子宫内膜癌患者,随机分为维持治疗组20例,口服甲羟孕酮片2次/日,500mg/次;对照组20例服用安慰剂,评价近期疗效和疾病进展时间。结果维持治疗组和对照组的有效率(RR)分别为0%和10%,疾病控制率(DCR)分别为100%和60%,中位PFS分别为25.7个月和13.2个月,差异有统计学意义。结论受体阳性晚期子宫内膜癌一线化疗后稳定的患者,使用甲羟孕酮维持治疗可使生存获益。
Objective To evaluate the efficacy of medroxyprogesterone in the maintenance of advanced endometrial cancer. Methods Forty patients with advanced endometrial cancer after first-line chemotherapy were randomly divided into maintenance treatment group (n = 20), oral medroxyprogesterone acetate injection (n = 2), n = 500 and control group (n = 20) Disease progression time. Results The effective rate (RR) of maintenance therapy group and control group were 0% and 10% respectively, the disease control rates (DCR) were 100% and 60% respectively, and the median PFS were 25.7 months and 13.2 months respectively. The difference was Statistical significance. CONCLUSIONS: Retention of medroxyprogesterone may benefit survival in patients with stable receptor-positive advanced endometrial cancer after first-line chemotherapy.